Hallal David

SEC source: 0001104659-26-110006 · tm2626025-1_4seq1.xml · nonDerivative · entry 1

Hallal David · CIK 0001457477 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,602,382

F1 · shares: On September 21, 2026, the reporting person transferred 36,652 shares of the Issuer's Common Stock to The Hallal Family Irrevocable Trust-2021 (the "Hallal 2021 Trust") for no consideration. The reporting person and his spouse serve as trustees of the Hallal 2021 Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F2 · balance_after: Consists of 161,878 shares of common stock, 315,504 RSUs subject to time-based vesting conditions and 1,125,000 RSUs subject to performance- and time-based vesting conditions.

SEC source: 0001193125-26-257494 · ownership.xml · derivative · entry 1

Hallal David · CIK 0001457477 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires 2036-06-02

F1 · derivative.exercise_date: The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

SEC source: 0001104659-26-045581 · tm2612274-1_4seq1.xml · nonDerivative · entry 1

Hallal David · CIK 0001457477 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,639,034

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units ("RSUs") on April 15, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. The shares vested pursuant to awards that were granted on April 27, 2025. Each RSU represents the contingent right to receive upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to these RSU awards vest annually over four years, subject to a continued service relationship with the Issuer on the applicable vesting date.

F2 · balance_after: Consists of 198,530 shares of common stock, 315,504 RSUs subject to time-based vesting conditions and 1,125,000 RSUs subject to performance- and time-based vesting conditions.

SEC source: 0001104659-26-013580 · tm266077-2_4seq1.xml · nonDerivative · entry 1

Hallal David · CIK 0001457477 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,669,649

F1 · shares: Represents restricted stock units ("RSUs") subject to time-based vesting conditions. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest in four annual installments over four years, with the first annual installment to vest on January 15, 2027 and each additional installment to vest annually thereafter; provided the reporting person continues to have a service relationship with the Issuer on each such vesting date.

F2 · balance_after: Consists of 166,645 shares of common stock, 378,004 RSUs subject to time-based vesting conditions and 1,125,000 RSUs subject to performance- and time-based vesting conditions.

SEC source: 0001104659-26-004221 · tm263352-1_4seq1.xml · nonDerivative · entry 1

Hallal David · CIK 0001457477 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,541,645

F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the vesting of restricted stock units subject to performance-and time-based vesting conditions ("PSUs"). The sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Each PSU represents the contingent right to receive upon vesting of the PSU, one share of the Issuer's common stock.

F2 · shares: (continued) The shares vested pursuant to awards that were granted on April 27, 2025. 125,000 shares subject to this PSU vested on January 12, 2026, with an additional 125,000 shares scheduled to vest on April 27, 2027 and the remaining shares vesting in tranches of a combination of performance-based vesting tied to the Issuer's common stock achieving certain price targets and time-based vesting over four year, provided the Reporting Person continues to have a service relationship with the Issuer on each such vesting date. Any PSUs that have not vested on or prior to April 27, 2029 will be forfeited for no consideration.

F3 · balance_after: 166,645 shares of common stock, 250,000 restricted stock units and 1,125,000 PSUs.

SEC source: 0001457477-25-000004 · form4-10092025_091053.xml · nonDerivative · entry 1

Hallal David · CIK 0001457477 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,599,095

F1 · kind: On October 8, 2025, the Reporting Person transferred 205,000 shares of the Issuer's Common Stock to the Hallal Family Irrevocable Trust - 2012 dated November 19, 2012 (the "Hallal Trust") for no consideration. The Reporting Person's spouse serves as a trustee of the Hallal Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F2 · balance_after: Consists of 99,095 shares of Common Stock and 1,500,000 restricted stock units.

SEC source: 0001193125-25-192818 · ownership.xml · derivative · entry 2

Hallal David · CIK 0001457477 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 146,160 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company ("Shares") and thereafter, the Merger Sub merged with and into the Company (the "Merger"). In accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company that had an exercise price per share that is less than the $10.047 in cash per share (the "Cash Amount") (each, an "In-the-Money Option") that was then outstanding was canceled and, in exchange therefor,

F2 · kind: (Continued from footnote 1) the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one non-transferable contractual contingent value right for each Share underlying such In-the-Money Option.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company ("Shares") and thereafter, the Merger Sub merged with and into the Company (the "Merger"). In accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company that had an exercise price per share that is less than the $10.047 in cash per share (the "Cash Amount") (each, an "In-the-Money Option") that was then outstanding was canceled and, in exchange therefor,

F2 · price: (Continued from footnote 1) the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one non-transferable contractual contingent value right for each Share underlying such In-the-Money Option.

F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company ("Shares") and thereafter, the Merger Sub merged with and into the Company (the "Merger"). In accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company that had an exercise price per share that is less than the $10.047 in cash per share (the "Cash Amount") (each, an "In-the-Money Option") that was then outstanding was canceled and, in exchange therefor,

F2 · derivative.exercise_date: (Continued from footnote 1) the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one non-transferable contractual contingent value right for each Share underlying such In-the-Money Option.

F1 · derivative.expiration_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company ("Shares") and thereafter, the Merger Sub merged with and into the Company (the "Merger"). In accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company that had an exercise price per share that is less than the $10.047 in cash per share (the "Cash Amount") (each, an "In-the-Money Option") that was then outstanding was canceled and, in exchange therefor,

F2 · derivative.expiration_date: (Continued from footnote 1) the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one non-transferable contractual contingent value right for each Share underlying such In-the-Money Option.

SEC source: 0001193125-25-192818 · ownership.xml · derivative · entry 1

Hallal David · CIK 0001457477 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,140 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company ("Shares") and thereafter, the Merger Sub merged with and into the Company (the "Merger"). In accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company that had an exercise price per share that is less than the $10.047 in cash per share (the "Cash Amount") (each, an "In-the-Money Option") that was then outstanding was canceled and, in exchange therefor,

F2 · kind: (Continued from footnote 1) the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one non-transferable contractual contingent value right for each Share underlying such In-the-Money Option.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company ("Shares") and thereafter, the Merger Sub merged with and into the Company (the "Merger"). In accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company that had an exercise price per share that is less than the $10.047 in cash per share (the "Cash Amount") (each, an "In-the-Money Option") that was then outstanding was canceled and, in exchange therefor,

F2 · price: (Continued from footnote 1) the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one non-transferable contractual contingent value right for each Share underlying such In-the-Money Option.

F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company ("Shares") and thereafter, the Merger Sub merged with and into the Company (the "Merger"). In accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company that had an exercise price per share that is less than the $10.047 in cash per share (the "Cash Amount") (each, an "In-the-Money Option") that was then outstanding was canceled and, in exchange therefor,

F2 · derivative.exercise_date: (Continued from footnote 1) the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one non-transferable contractual contingent value right for each Share underlying such In-the-Money Option.

F1 · derivative.expiration_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company ("Shares") and thereafter, the Merger Sub merged with and into the Company (the "Merger"). In accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company that had an exercise price per share that is less than the $10.047 in cash per share (the "Cash Amount") (each, an "In-the-Money Option") that was then outstanding was canceled and, in exchange therefor,

F2 · derivative.expiration_date: (Continued from footnote 1) the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one non-transferable contractual contingent value right for each Share underlying such In-the-Money Option.

SEC source: 0000950170-25-083410 · ownership.xml · derivative · entry 9

Hallal David · CIK 0001457477 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 38,228 shares

Expires 2025-06-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025

SEC source: 0000950170-25-083410 · ownership.xml · nonDerivative · entry 6

Hallal David · CIK 0001457477 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.19 to $10.29, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0000950170-25-083410 · ownership.xml · nonDerivative · entry 5

Hallal David · CIK 0001457477 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,228

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025

SEC source: 0000950170-25-083410 · ownership.xml · derivative · entry 8

Hallal David · CIK 0001457477 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,228

Underlying: Common Stock · 38,227 shares

Expires 2025-06-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025

SEC source: 0000950170-25-083410 · ownership.xml · nonDerivative · entry 4

Hallal David · CIK 0001457477 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.09 to $10.22, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0000950170-25-083410 · ownership.xml · nonDerivative · entry 3

Hallal David · CIK 0001457477 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,227

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025

SEC source: 0000950170-25-083410 · ownership.xml · derivative · entry 7

Hallal David · CIK 0001457477 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 76,455

Underlying: Common Stock · 38,227 shares

Expires 2025-06-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025

SEC source: 0000950170-25-083410 · ownership.xml · nonDerivative · entry 2

Hallal David · CIK 0001457477 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.01 to $10.16, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0000950170-25-083410 · ownership.xml · nonDerivative · entry 1

Hallal David · CIK 0001457477 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,227

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025

SEC source: 0001104659-25-045112 · tm2513936-1_4seq1.xml · derivative · entry 1

Hallal David · CIK 0001457477 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 275,167

Underlying: Common Stock · 275,167 shares

Expires 2035-05-02

F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest on April 27, 2026, with the remainder vesting in twelve equal quarterly installments thereafter; provided the reporting person continues to have a service relationship with the Issuer on each such vesting date.

SEC source: 0001104659-25-041457 · tm2513505-5_4seq1.xml · nonDerivative · entry 2

Hallal David · CIK 0001457477 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,804,095

F2 · shares: Represents performance based RSUs subject to performance- and time-based vesting conditions (the "PSUs"). The amount reported herein represents the maximum number of shares of the Issuer's common stock that may be issued under this award. The shares subject to this PSU vest in tranches of a combination of performance vesting tied to the Issuer's common stock achieving certain price targets and time-based vesting over four years, provided the reporting person continues to have a service relationship with the Issuer on each such vesting date. Any PSUs that have not vested on or prior to April 27, 2029 will be forfeited for no consideration.

SEC source: 0001104659-25-041457 · tm2513505-5_4seq1.xml · nonDerivative · entry 1

Hallal David · CIK 0001457477 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 554,095

F1 · shares: Represents restricted stock units ("RSUs") subject to time-based vesting conditions. Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest in four annual installments over four years, with the first annual installment to vest on April 15, 2026 and each additional installment to vest annually thereafter; provided the reporting person continues to have a service relationship with the Issuer on each such vesting date.

SEC source: 0000950170-25-053318 · ownership.xml · derivative · entry 1

Hallal David · CIK 0001457477 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2035-04-09

F1 · derivative.exercise_date: The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments from March 18, 2025 through March 18, 2028, subject to continuous service.

SEC source: 0001415889-24-018627 · form4-07012024_090748.xml · derivative · entry 2

Hallal David · CIK 0001457477 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2034-06-27

F3 · derivative.exercise_date: Options to vest and become fully exercisable on the earlier of the first anniversary following the date of grant or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date.

SEC source: 0001415889-24-018627 · form4-07012024_090748.xml · nonDerivative · entry 1

Hallal David · CIK 0001457477 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 304,095

F1 · shares: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest on the earlier of June 15, 2025 or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date.

F2 · balance_after: Consists of 290,595 shares of common stock and 13,500 RSUs.

SEC source: 0001415889-24-016896 · form4-06142024_080606.xml · nonDerivative · entry 1

Hallal David · CIK 0001457477 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 355,128

F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 12, 2025 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders.

SEC source: 0000950170-24-073254 · ownership.xml · derivative · entry 1

Hallal David · CIK 0001457477 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,200

Underlying: Common Stock · 24,200 shares

Expires 2034-06-11

SEC source: 0000950170-24-070600 · ownership.xml · nonDerivative · entry 1

Hallal David · CIK 0001457477 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,143,662

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) June 6, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.

SEC source: 0001415889-23-010194 · form4-06222023_100606.xml · derivative · entry 1

Hallal David · CIK 0001457477 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,000

Underlying: Common Stock · 36,000 shares

Expires 2033-06-21

F1 · derivative.exercise_date: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date.

SEC source: 0001209191-23-038189 · doc4.xml · derivative · entry 2

Hallal David · CIK 0001457477 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,735

Underlying: Class A Common Stock · 34,735 shares

Expires 2033-06-14

F2 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 14, 2024 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders.

SEC source: 0001209191-23-038189 · doc4.xml · nonDerivative · entry 1

Hallal David · CIK 0001457477 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 296,950

F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 14, 2024 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders.

SEC source: 0001209191-23-037590 · doc4.xml · derivative · entry 1

Hallal David · CIK 0001457477 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,383

Underlying: Common Stock · 22,383 shares

Expires 2033-06-13

SEC source: 0001209191-23-029102 · doc4.xml · nonDerivative · entry 1

Hallal David · CIK 0001457477 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,108,662

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) May 11, 2024 and (ii) the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-22-033994 · doc4.xml · nonDerivative · entry 1

Hallal David · CIK 0001457477 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 138,153

F1 · ownership.nature: Shares held by Terrie A. Hallal Family Irrevocable Trust 2012, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-22-032297 · doc4.xml · nonDerivative · entry 1

Hallal David · CIK 0001457477 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 720,965

F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.35 to $8.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F2 · ownership.nature: Shares held by The Hallal Family Irrevocable Trust 2012, for which the Reporting Person's spouse serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-22-027173 · doc4.xml · nonDerivative · entry 1

Hallal David · CIK 0001457477 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By ElevateBio LLC

Disclosed balance after: 16,674,766

F1 · kind: On July 28, 2022, ElevateBio LLC ("ElevateBio") acquired 3,253,796 shares of the Issuer's Common Stock in a registered direct offering for a purchase price of $4.61 per share.

F2 · ownership.nature: Shares held by ElevateBio. The Reporting Person is the Chairman and Chief Executive Officer of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-22-026519 · doc4.xml · nonDerivative · entry 1

Hallal David · CIK 0001457477 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,073,662

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on February 7, 2022 to cover tax withholding obligations upon the vesting and settlement of restricted stock units.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.26 to $5.42. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001104659-22-073027 · tm2218901-3_4seq1.xml · derivative · entry 1

Hallal David · CIK 0001457477 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,000

Underlying: Common Stock · 14,000 shares

Expires 2032-06-16

F1 · derivative.exercise_date: This option shall vest and become fully exercisable on the first anniversary following the date of grant subject to continued service to the Issuer through such date.

SEC source: 0001209191-22-038097 · doc4.xml · derivative · entry 2

Hallal David · CIK 0001457477 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,640

Underlying: Class A Common Stock · 29,640 shares

Expires 2031-06-15

F2 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 15, 2023 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders.

SEC source: 0001209191-22-038097 · doc4.xml · nonDerivative · entry 1

Hallal David · CIK 0001457477 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 273,507

F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 15, 2023 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders.

SEC source: 0001209191-22-036137 · doc4.xml · derivative · entry 13

Hallal David · CIK 0001457477 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,538

Underlying: Common Stock · 17,538 shares

Expires 2032-06-09

F5 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 9, 2023 or (b) the next annual meeting of the Issuer's stockholders.

SEC source: 0001209191-22-036137 · doc4.xml · derivative · entry 12

Hallal David · CIK 0001457477 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,160

Underlying: Common Stock · 1,171 shares

Expires 2030-05-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: One-fourth of the shares subject to the stock option vested on the one-year anniversary of the vesting commencement date. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis following the one-year anniversary of the vesting commencement date, subject to the reporting person continuous service relationship with the Issuer through each applicable vesting date.

SEC source: 0001209191-22-036137 · doc4.xml · nonDerivative · entry 8

Hallal David · CIK 0001457477 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.37 to $19.62, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001209191-22-036137 · doc4.xml · nonDerivative · entry 7

Hallal David · CIK 0001457477 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,171

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-22-036137 · doc4.xml · derivative · entry 11

Hallal David · CIK 0001457477 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 147,331

Underlying: Common Stock · 10,577 shares

Expires 2030-05-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: One-fourth of the shares subject to the stock option vested on the one-year anniversary of the vesting commencement date. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis following the one-year anniversary of the vesting commencement date, subject to the reporting person continuous service relationship with the Issuer through each applicable vesting date.

SEC source: 0001209191-22-036137 · doc4.xml · derivative · entry 10

Hallal David · CIK 0001457477 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,140

Underlying: Common Stock · 11,899 shares

Expires 2029-12-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: One-fourth of the shares subject to the stock option vested on the one-year anniversary of the vesting commencement date. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis following the one-year anniversary of the vesting commencement date, subject to the reporting person continuous service relationship with the Issuer through each applicable vesting date.

SEC source: 0001209191-22-036137 · doc4.xml · derivative · entry 9

Hallal David · CIK 0001457477 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,908

Underlying: Common Stock · 5,968 shares

Expires 2030-05-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: One-fourth of the shares subject to the stock option vested on the one-year anniversary of the vesting commencement date. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis following the one-year anniversary of the vesting commencement date, subject to the reporting person continuous service relationship with the Issuer through each applicable vesting date.

SEC source: 0001209191-22-036137 · doc4.xml · nonDerivative · entry 6

Hallal David · CIK 0001457477 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.75 to $20.12, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001209191-22-036137 · doc4.xml · nonDerivative · entry 5

Hallal David · CIK 0001457477 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,577

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-22-036137 · doc4.xml · nonDerivative · entry 4

Hallal David · CIK 0001457477 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.1 to $20.84, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001209191-22-036137 · doc4.xml · nonDerivative · entry 3

Hallal David · CIK 0001457477 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,899

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-22-036137 · doc4.xml · nonDerivative · entry 2

Hallal David · CIK 0001457477 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.1 to $20.84, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.